The dosing schedule for retatrutide is a key question for clinicians and patients following the promising Phase 2 trial results published in 2023. Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently under clinical development for obesity and type 2 diabetes. It is not yet approved in the UK or anywhere else. This article explains what the clinical trial data reveal about dosing, safety considerations, and side effects, and clarifies the current regulatory status — helping readers understand what retatrutide is, where the research stands, and how to access approved weight management treatments in the UK.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, enhancing insulin secretion, suppressing appetite, increasing energy expenditure, and promoting hepatic fat oxidation.

Retatrutide is an investigational injectable medication currently under clinical development for the treatment of obesity and type 2 diabetes mellitus. It belongs to a novel class of agents known as triple agonists, meaning it simultaneously activates three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism of action distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 receptor agonist).

By activating GLP-1 receptors, retatrutide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and reduces appetite by acting on satiety centres in the brain. The GIP receptor component further augments insulin secretion and may improve fat metabolism. The glucagon receptor agonism, whilst counterintuitive given glucagon's role in raising blood glucose, is thought to increase energy expenditure and promote hepatic fat oxidation whilst reducing lipogenesis — effects that may offer potential benefits in metabolic dysfunction-associated steatotic liver disease (MASLD). Long-term cardiovascular outcomes and the full safety profile of this mechanism in humans remain to be established in ongoing Phase 3 trials.

Phase 2 clinical trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) demonstrated substantial weight reduction in participants with obesity. In the highest-dose group studied (12 mg once weekly), mean weight loss approached 17.5% of body weight over 24 weeks. These results have generated considerable scientific interest, though retatrutide remains an experimental compound and is not yet approved for clinical use in the UK or elsewhere.

Dosing in Clinical Trials: What the Research Shows

In the Phase 2 trial, retatrutide was administered as a once-weekly subcutaneous injection, with doses escalating gradually from 1 mg to up to 12 mg to reduce gastrointestinal side effects; this is not an approved prescribing schedule.

Because retatrutide is an investigational medicinal product (IMP) that has not received a marketing authorisation in the UK, there is no approved prescribing information or patient dosing schedule. The information below describes the dosing approach used in the Phase 2 clinical trial (Jastreboff et al., NEJM 2023) for context only. It does not constitute prescribing guidance and should not be used to self-administer or source this medicine outside of an approved clinical trial.

In the Phase 2 trial, retatrutide was administered as a once-weekly subcutaneous injection — an approach consistent with other incretin-based therapies in this class. Participants began on a low starting dose and underwent gradual escalation at defined intervals to minimise gastrointestinal side effects. Several dose escalation arms were studied, with doses ranging from 1 mg up to 12 mg once weekly. The slow titration strategy is a deliberate clinical approach to allow the body to adapt to the medication's effects on gastric emptying and appetite regulation; the specific escalation steps and intervals were defined by the trial protocol.

Injections in the trial were administered subcutaneously into the abdomen, upper thigh, or upper arm, with site rotation between doses.

It is essential to understand that these trial-specific details may not reflect the dosing schedule of any future approved product. Retatrutide must not be sourced, prescribed, or self-administered outside of an approved clinical trial in the UK. Anyone wishing to participate in a clinical trial of retatrutide should discuss this with their GP or specialist, or search for registered studies at clinicaltrials.gov or the MHRA Clinical Trials register.

Adjusting Your Dose: When to Seek Medical Advice

Dose adjustment in trials is managed solely by the research team; participants should seek prompt medical advice for persistent vomiting, severe abdominal pain, signs of dehydration, or symptoms of hypoglycaemia.

Within clinical trials, dose adjustment is managed entirely by the supervising research team in accordance with the trial protocol. Participants should not independently alter their dose escalation schedule. Outside of an approved clinical trial, retatrutide should not be used at all in the UK.

The gradual dose escalation used in trials is clinically important — it is designed to reduce the incidence and severity of nausea, vomiting, and other gastrointestinal adverse effects that are common with this class of medication. Accelerating escalation increases the risk of adverse effects and potential dehydration.

Anyone receiving retatrutide within a clinical trial should seek prompt medical advice from their trial team if they experience any of the following:

• Persistent or severe vomiting that prevents adequate fluid or food intake

• Signs of dehydration, including dizziness, reduced urination, or extreme thirst

• Severe or persistent abdominal pain, which may rarely indicate pancreatitis or a gallbladder problem

• Right upper quadrant pain, fever, or jaundice, which may suggest acute gallbladder disease (cholelithiasis or cholecystitis) — a recognised risk with GLP-1-based therapies and with rapid weight loss

• Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas), such as shakiness, sweating, or confusion

• Injection site reactions that are worsening, infected, or not resolving

Retatrutide has not been studied in pregnancy or breastfeeding, and use during pregnancy or whilst breastfeeding is not recommended until safety data are available. Women of childbearing potential should discuss contraception with their clinician before entering a trial of any weight-management medicine.

Regarding thyroid safety: animal studies with GLP-1 receptor agonists have identified C-cell tumours in rodents at high doses, but the relevance of these findings to humans is uncertain. Current UK prescribing information (SmPCs) for licensed GLP-1 receptor agonists does not list a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) as a contraindication, though individuals with such a history should discuss this with their clinician as a precautionary measure. The position for retatrutide specifically will be clarified in future regulatory submissions.

Renal and hepatic function may be relevant to dosing in any future approved formulation, but no specific guidance exists for retatrutide at this stage.

Common Side Effects and Safety Considerations

The most frequently reported side effects are gastrointestinal — particularly nausea — and are generally mild to moderate, most prominent during dose escalation, and tend to diminish over time.

As with other agents in the incretin receptor agonist class, the most frequently reported side effects of retatrutide in the Phase 2 clinical trial were gastrointestinal in nature. These were generally mild to moderate in severity, most prominent during the dose escalation phase, and tended to diminish over time.

Commonly reported side effects in the Phase 2 trial included:

• Nausea (the most frequently reported adverse effect)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

• Abdominal discomfort or bloating

• Eructation (belching)

The majority of participants who discontinued treatment did so due to gastrointestinal side effects, underscoring the importance of the slow titration schedule used in trials. Injection site reactions, including redness, bruising, or mild swelling, were also reported but were generally transient.

Gallbladder disease: Cholelithiasis (gallstones) and cholecystitis have been reported with GLP-1 receptor agonist therapies and may also occur with rapid weight loss. Participants should report any right upper quadrant pain, fever, or jaundice to their trial team promptly.

Cardiovascular effects: Retatrutide's glucagon receptor agonism may influence heart rate and blood pressure. Phase 2 trial data reported modest increases in heart rate in some participants. Cardiovascular outcomes data from large-scale trials are not yet available, and this remains an area of active investigation.

Pancreatitis: As with all GLP-1 receptor agonists, there is a theoretical risk of acute pancreatitis. A definitive causal link has not been established in human trials to date, but severe or persistent abdominal pain should always be evaluated promptly.

Lean muscle mass: Weight loss with medicines of this class can include some loss of lean muscle mass alongside fat mass. General best-practice guidance — consistent with NHS and professional body recommendations — supports regular resistance exercise and adequate dietary protein intake to help preserve muscle tissue during weight management.

Pregnancy and breastfeeding: Use is not recommended in pregnancy or whilst breastfeeding, as safety data are not yet available.

Eating disorders: Patients with a history of eating disorders should be assessed carefully before initiating any appetite-suppressing therapy, and psychological support should be considered as part of a holistic management plan.

If you are receiving retatrutide as part of a clinical trial and experience any suspected side effects, report these to your trial team. Suspected adverse reactions to any medicine can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Current Availability and Regulatory Status in the UK

Retatrutide is not approved by the MHRA and cannot be legally prescribed in the UK outside of an approved clinical trial; purchasing it from unregulated sources carries serious patient safety risks.

As of the time of writing, retatrutide is not approved for clinical use in the United Kingdom. It is an investigational medicinal product (IMP) and has not received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). It is not available on NHS prescription and cannot be legally prescribed through routine private prescribing channels. The only lawful route of access in the UK is participation in an approved clinical trial.

Retatrutide is being developed by Eli Lilly and Company. Phase 3 clinical trials are ongoing, and regulatory submissions to bodies such as the US Food and Drug Administration (FDA) and the MHRA are anticipated in the coming years, subject to trial outcomes.

Patients and healthcare professionals should exercise significant caution regarding any online sources or private clinics claiming to offer retatrutide. Purchasing unlicensed or unregulated injectable medications carries serious patient safety risks, including unknown product quality, incorrect dosing, contamination, and lack of appropriate medical oversight. The MHRA actively monitors and takes enforcement action against the supply of unlicensed medicines in the UK.

Currently approved weight management pharmacotherapy in the UK includes:

• Semaglutide (Wegovy) — a GLP-1 receptor agonist approved by the MHRA for chronic weight management in adults, subject to NICE Technology Appraisal eligibility criteria

• Tirzepatide (Mounjaro) — a dual GIP/GLP-1 receptor agonist approved by the MHRA for the treatment of type 2 diabetes; also approved for chronic weight management in adults (refer to current MHRA and NICE Technology Appraisal guidance for the applicable indication and eligibility criteria)

• Orlistat — available on NHS prescription and over the counter

• Naltrexone/bupropion (Mysimba) — available in some settings, though NHS commissioning varies by region

NICE Technology Appraisals provide eligibility criteria and commissioning guidance for semaglutide and tirzepatide in weight management; readers should refer to the current published NICE TAs for up-to-date thresholds and conditions of use.

For individuals seeking evidence-based weight management support, NICE recommends a structured approach incorporating dietary intervention, physical activity, and behavioural support, with pharmacotherapy considered where appropriate within NHS tiered weight management services. Patients are encouraged to speak with their GP or a specialist weight management service to explore currently available, approved treatment options.

Frequently Asked Questions